Efficacy and Safety Study of Medical Thoracoscope Cryotherapy Combined Standard First-line Treatm… (NCT05291403) | Clinical Trial Compass
UnknownNot Applicable
Efficacy and Safety Study of Medical Thoracoscope Cryotherapy Combined Standard First-line Treatment of Advanced Non-small Cell Lung Cancer and Malignant Pleural Effusion
China141 participantsStarted 2022-04-06
Plain-language summary
This study intends to investigate the efficacy and safety of medical thoracoscopic cryotherapy combined with standard first-line treatment of advanced non-small cell lung cancer with malignant pleural effusion through a randomized controlled clinical trial.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. 18-75 years old;
✓. Non-small cell lung cancer with pleural metastasis confirmed by histopathology or cytology;
✓. ECOG score 0-1;
✓. Cardiopulmonary function can tolerate painless thoracoscopic examination;
✓. Patients who underwent medical thoracoscopy for pleural effusion at first diagnosis and underwent medical thoracoscopy cryotherapy at the same time of biopsy were also included in the study. Non-small cell lung cancer was confirmed by pathological results;
✓. All subjects or their guardians must sign the informed consent before entering the study.
✕. severe cardiac insufficiency, abnormal liver and kidney function (blood test results of transaminase and creatinine \> 1.5 times the normal upper limit);
✕. have received chemotherapy or anti-angiogenic drugs (such as bevacizumab, endu, anlotinib, etc.);